Kisspeptin-10 vs Sermorelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Kisspeptin-10
Kisspeptin-10 is the biologically active 10-amino acid C-terminal fragment of kisspeptin, a neuropeptide that acts as the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. By activating KISS1R (GPR54) in the hypothalamus, it triggers pulsatile GnRH release, which drives LH, FSH, and downstream testosterone and estrogen production. It is the upstream signal that 'turns on' the reproductive axis — with research applications spanning fertility, hypogonadism, post-cycle therapy support, and age-related hormonal decline.
Full profileSermorelin
Sermorelin is a synthetic analog of the first 29 amino acids of GHRH (Growth Hormone-Releasing Hormone). It was FDA-approved for pediatric GH deficiency diagnosis and is widely used off-label in anti-aging and performance medicine. It stimulates pulsatile GH release more physiologically than exogenous GH.
Full profile| Kisspeptin-10 | Sermorelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | KP-10, Metastin(112-121), KISS1R agonist | GHRH 1-29, GRF 1-29 NH2, Geref |
| Evidence | FDA-approved | FDA-approved |
| Dosing range | 50mcg–250mcg mcg, 1–2x daily (pulsatile administration is important — avoid continuous infusion) | 100mcg–500mcg mcg, once daily (before sleep) |
| Administration | Subcutaneous injection, Intranasal, Intravenous (clinical studies — produces most reliable LH pulses) | Subcutaneous injection |
| Key side effects | Generally well-tolerated in clinical trials, Nausea (mild, uncommon), Potential for over-stimulation of the HPG axis at high doses (rarely significant), Theoretical desensitization with continuous (non-pulsatile) dosing | Injection site redness, Headache, Flushing, Dizziness |
| Cited sources | 3 references | 1 reference |
Key differences
- Administration: Kisspeptin-10 — Subcutaneous injection, Intranasal, Intravenous (clinical studies — produces most reliable LH pulses); Sermorelin — Subcutaneous injection.
- Frequency: Kisspeptin-10 is typically 1–2x daily (pulsatile administration is important — avoid continuous infusion); Sermorelin is once daily (before sleep).
- Research depth: this profile cites 3 sources for Kisspeptin-10 vs 1 for Sermorelin.
How each works
Kisspeptin-10
Kisspeptin neurons in the arcuate nucleus form the pulse generator for GnRH secretion — without kisspeptin signaling, reproductive function ceases. Human clinical trials confirm that IV kisspeptin-10 produces rapid, dose-dependent LH pulses in both males and females, restoring hormonal function in hypogonadotropic hypogonadism. Kisspeptin-54 (the longer form) has been studied in human fertility treatments with successful outcomes. Unlike direct LH/FSH administration, kisspeptin works upstream at the hypothalamus, preserving the natural pulsatile release pattern and avoiding receptor desensitization associated with continuous GnRH agonists.
Sermorelin
Sermorelin works by binding pituitary GHRH receptors to stimulate GH secretion within the body's natural feedback loop. Unlike synthetic GH, it does not suppress endogenous production. Clinical studies show improved body composition, sleep quality, and IGF-1 levels in GH-deficient adults. Its short half-life (~10 min) means it requires daily dosing.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.